Follow the Devyser Diagnostics AB stock price and the full management transaction log of the company, a listed issuer based in Finland. Shares are listed on the FI market, under the authority of FIN-FSA. Operating in the Health Care sector, Devyser Diagnostics AB has recorded 29 reports. Market capitalisation: €1.1bn. The latest transaction was disclosed on 12 August 2026 (Purchase). Among the most active insiders: Mia Arnhult. All data is free.
29
Insider Decl.
n/a
Thresholds
€555,341
21 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Devyser Diagnostics AB Strong Buy (bullish), based on 2 analysts. Average price target: SEK 96.48.
43Σ signal
Buys €555,341n/a Sells
Fundamental score
Ranked 21,553 of 28,822 companies
34.7
score / 100
Value
19
Quality
51
FCF yld-6.1%
Earn yld-0.8%
EV/EBITDA38.6x
ROE4.3%
Gross mgn81%
Net mgn-3.4%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
14,084 shares@ €9.98570.0093% mcap95.6% of flowAktieISINISIN SE0016588867FI:A003T495-1
25 of 29 declarations
About Devyser Diagnostics AB
Devyser Diagnostics AB is a company focused on developing molecular diagnostic tests. It specializes in solutions for the diagnosis of genetic diseases and cancers.